A Phase III, Randomized, Double-blinded, Multicenter Study of AK105 Combined With Carboplatin and Pemetrexed vs Placebo Combined With Carboplatin and Pemetrexed as First-line Therapy in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
Latest Information Update: 08 Apr 2024
At a glance
- Drugs Carboplatin (Primary) ; Catequentinib (Primary) ; Pemetrexed (Primary) ; Penpulimab (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Akeso Biopharma
Most Recent Events
- 02 Apr 2024 Status changed from active, no longer recruiting to discontinued.
- 11 Oct 2022 The number of treatment arms increased from 2 to 3. Anlotinib has been introduced in the treatment.
- 11 Oct 2022 Planned End Date changed from 30 Nov 2021 to 30 Jun 2024.